8 active not recruiting, 2 completed, 1 withdrawn. 6 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 4, Completed 1, Withdrawn 1 |
| Phase 3 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow Metastatic Urethral Urothelial Carcinoma: new trials by email Literature Review of Metastatic Urethral Urothelial Carcinoma trials Research Report on Metastatic Urethral Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-01 |
| Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Pembrolizumab, Nivolumab, Atezolizumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 3 | 2022-05-27 | 2026-03-20 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Pembrolizumab, Propranolol Hydrochloride, Nivolumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | Emory University | 6 | 2021-05-20 | 2026-02-19 |
| Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy Cyclophosphamide, Fludarabine, Fludarabine Phosphate - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2019-06-20 | 2020-01-02 | |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Carboplatin, Cisplatin, Docetaxel - Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 15 | 2019-01-11 | 2025-11-12 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Bevacizumab, Cisplatin, Gemcitabine Hydrochloride - Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 506 | 2009-07-15 | 2026-06-24 |
Urethral Neoplasms (9) · Ureteral Neoplasms (8) · Urinary Bladder Neoplasms (8) · Carcinoma, Transitional Cell (7) · Prostatic Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Melanoma (1)
Neoplasms (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Male Urogenital Diseases (9) · Neoplasms by Site (9) · Urethral Diseases (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Urologic Diseases (9) · Urologic Neoplasms (9) · Neoplasms by Histologic Type (8) · Ureteral Diseases (8) · Urinary Bladder Diseases (8) · Carcinoma (7) · Neoplasms, Glandular and Epithelial (7)
Nivolumab (4) · Specimen Handling (4) · pembrolizumab (4) · Immunoglobulin G (3) · atezolizumab (3) · avelumab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Biopsy (2) · Cisplatin (2) · Disulfides (2) · Magnetic Resonance Spectroscopy (2) · Platinum (2) · Bevacizumab (1) · CTLA-4 Antigen (1) · Carboplatin (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (11) · Canada (2) · Puerto Rico (1)
Anishka A D'Souza (1) · Arnold Chin (1) · Evan Y Yu (1) · Gurkamal Chatta, MD (1) · Jacqueline Brown, MD (1) · Jonathan E Rosenberg (1) · Rodabe Amaria, MD (1) · Rohit Jain (1) · Sangeeta Goswami (1) · Shilpa Gupta (1) · Xiao X. Wei, MD, MAS (1)
PMID 33989025, PMID 35537412, PMID 37328287, PMID 39536751, PMID 40256659, PMID 40591902
U10CA180821 (3), P30CA015704 (1), P30CA016056 (1), P30CA138292 (1), U01CA154967 (1), U10CA031946 (1), UM1CA186644 (1), UM1CA186717 (1)